Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers R > Headlines for Rigel Pharmaceuticals, Inc. > News item |
Rigel Pharmaceuticals arranges $30 million at-the-market sale of stock
Agent Cantor Fitzgerald assists; offering finances corporate purposes
By Devika Patel
Knoxville, Tenn., Aug. 18 – Rigel Pharmaceuticals, Inc. negotiated a $30 million at-the-market equity offering with Cantor Fitzgerald & Co. on Aug. 18, according to an 8-K and prospectus supplement filed Tuesday with the Securities and Exchange Commission.
Cantor will be paid a 2% commission.
Proceeds will be used for general corporate purposes.
Rigel is a South San Francisco, Calif., drug development company.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.